Review summary
Teaching objective: Person-first, confidential primary care for a 45-year-old man four months after HIV was diagnosed with cerebral toxoplasmosis, who also has coronary artery disease after two bypass operations: viral load and CD4 monitoring on bictegravir, emtricitabine, and tenofovir alafenamide (an antiretroviral regimen chosen to avoid interactions with his statin and cardiac medicines and to avoid abacavir), trimethoprim-sulfamethoxazole maintenance and its safe discontinuation by CD4 count, vaccines for adults with HIV, and secondary prevention of coronary disease to an LDL goal below 55 mg/dL, on the DHHS and IAS-USA antiretroviral guidance, the DHHS opportunistic infection guidelines, the HIVMA/IDSA primary care guidance, and the CMID ischemic heart disease and hyperlipidemia monographs.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| July 10, 1943 | Born in Richmond, Virginia. | CLM-0001 |
| July 31, 1979 | Heart attack while teaching tennis to young people. | CLM-0002 |
| 1979 | Quadruple coronary artery bypass surgery. | CLM-0002 |
| 1983 | Second (double) bypass operation, with a blood transfusion. | CLM-0003, CLM-0005 |
| 1988 | Brain surgery for a mass found to be toxoplasmosis; HIV diagnosed. | CLM-0004 |
| April 8, 1992 | Announced publicly that he had HIV. | CLM-0006 |
| February 6, 1993 | Died in New York City. | CLM-0008 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Arthur Robert Ashe Jr. was born in Richmond, Virginia, on July 10, 1943, to Mattie Cunningham Ashe and Arthur Robert Ashe Sr.; his mother died before he was seven. | confirmed | Arthur Ashe (1943-1993) supports |
| D | On July 31, 1979, while teaching tennis to inner-city youth, Ashe had a heart attack, and he then underwent quadruple coronary artery bypass surgery in 1979. The anchor for the synthetic coronary artery disease and old myocardial infarction. One source dates a first heart attack to July 1976; the 1979 date is preferred (see sources.md). |
confirmed | Arthur Ashe (1943-1993) supports Lerner BH. Arthur Ashe and AIDS: Did the public have the right to know his diagnosis? supports Arthur Ashe supports Markel H. Arthur Ashe's other great serve: as activist for health disputes |
| D | When chest pain recurred, Ashe had a second bypass operation, a double bypass, in 1983, during which he received a blood transfusion. The anchor for two bypass operations. |
confirmed | Arthur Ashe (1943-1993) supports Lerner BH. Arthur Ashe and AIDS: Did the public have the right to know his diagnosis? supports Markel H. Arthur Ashe's other great serve: as activist for health supports |
| D | In 1988 Ashe had difficulty moving his right hand and arm; a scan showed a mass in the left side of his brain, which surgeons removed, and the diagnosis was toxoplasmosis. Testing then showed that he had HIV and AIDS. The anchor for the synthetic HIV disease with a history of cerebral toxoplasmosis. The month of the operation was not verified in a fetched source. |
confirmed | Lerner BH. Arthur Ashe and AIDS: Did the public have the right to know his diagnosis? supports Markel H. Arthur Ashe's other great serve: as activist for health supports Arthur Ashe supports |
| D | Ashe and his doctors concluded that he had almost certainly acquired HIV from a blood transfusion during his 1983 heart operation, before blood was tested for the virus. Documents the route of acquisition; the modern frame keeps it as history only (see sources.md). |
confirmed | Lerner BH. Arthur Ashe and AIDS: Did the public have the right to know his diagnosis? supports Markel H. Arthur Ashe's other great serve: as activist for health supports Arthur Ashe supports |
| D | Ashe kept his diagnosis private at first, telling only a few family members and friends. On April 8, 1992, after learning that USA Today planned to report it, he announced at a press conference that he had HIV. After the true-frame index date; recorded in the timeline. Supports the episode's emphasis on his control over disclosure. |
confirmed | Arthur Ashe (1943-1993) supports Lerner BH. Arthur Ashe and AIDS: Did the public have the right to know his diagnosis? supports Markel H. Arthur Ashe's other great serve: as activist for health supports |
| D | Both of Ashe's parents had atherosclerotic heart disease at early ages. His mother died at 27 of complications from surgery, and his father had two heart attacks, at 55 and at 59. Family history of early coronary disease. |
confirmed | Lerner BH. Arthur Ashe and AIDS: Did the public have the right to know his diagnosis? supports Markel H. Arthur Ashe's other great serve: as activist for health supports |
| D | Ashe died in New York City on February 6, 1993, aged 49, of AIDS-related pneumonia. His memoir, Days of Grace, was published after his death. Recorded as a fact without detail; after the episode. |
confirmed | Arthur Ashe (1943-1993) supports Markel H. Arthur Ashe's other great serve: as activist for health supports Arthur Ashe supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infection | active | confirmed | both_with_link | CLM-0004, CLM-0005 |
| S | Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapy | active | confirmed | both_with_link | CLM-0004 |
| S | Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1979 and 1983 operations | active | confirmed | both_with_link | CLM-0002, CLM-0003 |
| S | Old myocardial infarction at age 36 | active | confirmed | both_with_link | CLM-0002 |
| S | Hyperlipidemia, on high-intensity statin | active | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-01-12 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection | 42 {copies}/mL (high) Reference Below 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detected |
http://loinc.org · 20447-9 |
| S | 2026-01-12 | CD3+CD4+ (T4 helper) cells [#/volume] in Blood | 156 /uL (low) Reference 500-1500 /uL |
http://loinc.org · 24467-3 |
| S | 2026-01-12 | Leukocytes [#/volume] in Blood by Automated count | 4.2 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-01-12 | Hemoglobin [Mass/volume] in Blood | 13 g/dL (low) Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-01-12 | Platelets [#/volume] in Blood by Automated count | 198 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-01-12 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-01-12 | Potassium [Moles/volume] in Serum or Plasma | 4.9 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-01-12 | Creatinine [Mass/volume] in Serum or Plasma | 1.18 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-01-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 78 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-01-12 | Glucose [Mass/volume] in Serum or Plasma | 92 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-01-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-01-12 | Cholesterol [Mass/volume] in Serum or Plasma | 158 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-01-12 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 40 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-01-12 | Triglyceride [Mass/volume] in Serum or Plasma | 150 mg/dL (high) Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-01-12 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 88 mg/dL Reference <=99 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-01-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-01-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 2026-01-12 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
| S | 2026-02-09 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-02-09 | Potassium [Moles/volume] in Serum or Plasma | 4.8 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-02-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.16 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-02-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 79 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-02-09 | Glucose [Mass/volume] in Serum or Plasma | 90 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-04-13 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 {copies}/mL Reference Below 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detected |
http://loinc.org · 20447-9 |
| S | 2026-04-13 | CD3+CD4+ (T4 helper) cells [#/volume] in Blood | 218 /uL (low) Reference 500-1500 /uL |
http://loinc.org · 24467-3 |
| S | 2026-04-13 | Leukocytes [#/volume] in Blood by Automated count | 4.6 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-04-13 | Hemoglobin [Mass/volume] in Blood | 13.6 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-04-13 | Platelets [#/volume] in Blood by Automated count | 224 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-04-13 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.7 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.15 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 80 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-04-13 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-04-13 | Cholesterol [Mass/volume] in Serum or Plasma | 118 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-04-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 41 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-04-13 | Triglyceride [Mass/volume] in Serum or Plasma | 125 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-04-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 52 mg/dL Reference <=99 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-04-13 | Lipoprotein a [Mass/volume] in Serum or Plasma | 24 mg/dL Reference <=29 mg/dL |
http://loinc.org · 10835-7 |
| S | 2026-04-13 | Hepatitis B virus surface Ab [Units/volume] in Serum | 86 m[IU]/mL Reference >=10 m[IU]/mL |
http://loinc.org · 16935-9 |
| S | 2026-07-13 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 {copies}/mL Reference Below 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detected |
http://loinc.org · 20447-9 |
| S | 2026-07-13 | CD3+CD4+ (T4 helper) cells [#/volume] in Blood | 262 /uL (low) Reference 500-1500 /uL |
http://loinc.org · 24467-3 |
| S | 2026-07-13 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.14 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 80 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-07-13 | Glucose [Mass/volume] in Serum or Plasma | 93 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-07-13 | Albumin/Creatinine [Mass Ratio] in Urine | 12 mg/g Reference <=29 mg/g |
http://loinc.org · 9318-7 |
| S | 2026-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 2026-08-17 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-08-17 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
| S | 2026-10-19 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 {copies}/mL Reference Below 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detected |
http://loinc.org · 20447-9 |
| S | 2026-10-19 | CD3+CD4+ (T4 helper) cells [#/volume] in Blood | 318 /uL (low) Reference 500-1500 /uL |
http://loinc.org · 24467-3 |
| S | 2026-10-19 | Leukocytes [#/volume] in Blood by Automated count | 5 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-10-19 | Hemoglobin [Mass/volume] in Blood | 14.1 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-10-19 | Platelets [#/volume] in Blood by Automated count | 236 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-10-19 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-10-19 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-10-19 | Creatinine [Mass/volume] in Serum or Plasma | 1.12 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 82 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-10-19 | Glucose [Mass/volume] in Serum or Plasma | 91 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-01-12 | Body height | 185 cm | 8302-2 | S |
| 2026-01-12 | Body weight | 72 kg | 29463-7 | S |
| 2026-01-12 | Body mass index (BMI) [Ratio] | 21 kg/m2 | 39156-5 | S |
| 2026-01-12 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-01-12 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-01-12 | Heart rate | 72 /min | 8867-4 | S |
| 2026-01-12 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-01-12 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-01-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-02-09 | Body height | 185 cm | 8302-2 | S |
| 2026-02-09 | Body weight | 72.6 kg | 29463-7 | S |
| 2026-02-09 | Body mass index (BMI) [Ratio] | 21.2 kg/m2 | 39156-5 | S |
| 2026-02-09 | Systolic blood pressure | 116 mm[Hg] | 8480-6 | S |
| 2026-02-09 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-02-09 | Heart rate | 70 /min | 8867-4 | S |
| 2026-02-09 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-02-09 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-02-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-04-13 | Body height | 185 cm | 8302-2 | S |
| 2026-04-13 | Body weight | 73.8 kg | 29463-7 | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 21.6 kg/m2 | 39156-5 | S |
| 2026-04-13 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-04-13 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-04-13 | Heart rate | 68 /min | 8867-4 | S |
| 2026-04-13 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-04-13 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-07-13 | Body height | 185 cm | 8302-2 | S |
| 2026-07-13 | Body weight | 74.6 kg | 29463-7 | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 21.8 kg/m2 | 39156-5 | S |
| 2026-07-13 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-07-13 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-07-13 | Heart rate | 66 /min | 8867-4 | S |
| 2026-07-13 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-07-13 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-19 | Body height | 185 cm | 8302-2 | S |
| 2026-10-19 | Body weight | 75 kg | 29463-7 | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 21.9 kg/m2 | 39156-5 | S |
| 2026-10-19 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-10-19 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-10-19 | Heart rate | 66 /min | 8867-4 | S |
| 2026-10-19 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-19 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-08-17 | Body height | 185 cm | 8302-2 | S |
| 2026-08-17 | Body weight | 74.8 kg | 29463-7 | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 21.9 kg/m2 | 39156-5 | S |
| 2026-08-17 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-08-17 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-08-17 | Heart rate | 64 /min | 8867-4 | S |
| 2026-08-17 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-17 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Former professional tennis player; now writes, broadcasts, and coaches young players; travels for work
- S Supports: married, with a young child, and close friends; has told only a few people about his HIV diagnosis
- S Tobacco: never; alcohol: AUDIT-C 1, a glass of wine once or twice a week; no other substance use
- S Exercise: hits tennis balls for an hour three times a week and walks daily, without chest pain
- S Sexual health: one partner; condoms used until his viral load is undetectable for six months; told that a person with HIV whose viral load stays undetectable does not transmit HIV sexually
Functional status
- S Right-hand weakness at diagnosis has recovered: grip and fine finger movements equal on both sides; writes and plays without difficulty
- S Independent in all activities; vigorous exercise without angina or breathlessness
Mental status
- S Alert, composed, and thoughtful; asks precise questions about his treatment
- S Mood mostly good, with worry about his family and his privacy; PHQ-9 score 5 with item 9 scored 0; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium
- S Pyrimethamine 25 mg oral tablet, 200 mg once, then three tablets (75 mg) by mouth daily for six weeks; course completed before intake
- S Sulfadiazine 500 mg oral tablet, three tablets (1500 mg) by mouth every 6 hours for six weeks; course completed before intake
- S Leucovorin 10 mg oral tablet, two tablets (20 mg) by mouth daily with pyrimethamine; course completed before intake
- S Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily
- S Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily
- S Atorvastatin 80 mg oral tablet, one tablet by mouth daily
- S Ezetimibe 10 mg oral tablet, one tablet by mouth daily
- S Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet
Procedures and immunizations
Procedures
- S Coronary artery bypass grafting, four grafts, after a myocardial infarction at age 36
- S Repeat coronary artery bypass grafting, two grafts, for recurrent angina; blood transfusion given
- S MRI of the head with contrast: single ring-enhancing lesion in the left frontoparietal region with surrounding edema
- S Stereotactic biopsy of the left frontoparietal lesion: necrotizing inflammation with Toxoplasma gondii organisms; no lymphoma
- S 12-lead electrocardiogram: sinus rhythm 72/min, old inferior Q waves, no acute ST change
- S Advance care planning conversation, about 20 minutes
Immunizations
- S 2021-05-03: Tdap vaccine
- S 2025-09-18: Influenza vaccine, 2025-2026 season, given in the hospital
- S 2026-01-12: Pneumococcal conjugate vaccine PCV20
- S 2026-01-12: Hepatitis B vaccine (HepB-CpG), dose 1 of 2
- S 2026-01-12: Meningococcal conjugate vaccine MenACWY, dose 1 of 2
- S 2026-02-09: Hepatitis B vaccine (HepB-CpG), dose 2 of 2
- S 2026-04-13: Meningococcal conjugate vaccine MenACWY, dose 2 of 2
- S 2026-04-13: Recombinant zoster vaccine, dose 1 of 2
- S 2026-08-17: Recombinant zoster vaccine, dose 2 of 2
- S 2026-10-19: Influenza vaccine, 2026-2027 season
- S 2026-10-19: COVID-19 vaccine, 2026-2027 formula
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D July 31, 1979: Heart attack at age 36 while teaching tennis to young people, followed by quadruple coronary artery bypass surgery (CLM-0002)
- D 1983: Second (double) bypass operation for recurrent chest pain, with a blood transfusion (CLM-0003)
- D 1988: Right-arm weakness from a left-sided brain mass, removed and found to be toxoplasmosis; HIV and AIDS diagnosed, believed to have been acquired from the transfusion during the 1983 operation (CLM-0004, CLM-0005)
Family history
- D mother: Died at 27 of complications from surgery; atherosclerotic heart disease at an early age reported
- D father: Heart attacks at 55 and 59; atherosclerotic heart disease at an early age reported
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| HIV-1 viral load not detected by the three-month visit | 2026-04-13 | completed | Viral load not detected (below 20 copies/mL) at three months, and at six and nine months |
| CD4 count above 200 cells/uL for more than six months with an undetectable viral load, so that maintenance therapy can stop safely | 2026-10-19 | completed | CD4 218 at three months, 262 at six months, and 318 at nine months; trimethoprim-sulfamethoxazole stopped |
| LDL cholesterol below 55 mg/dL by the three-month visit | 2026-04-13 | completed | LDL cholesterol 52 mg/dL on atorvastatin and ezetimibe |
| Hepatitis B vaccine series completed with a protective antibody level by the three-month visit | 2026-04-13 | completed | Hepatitis B surface antibody 86 mIU/mL |
| Keep blood pressure below 130/80 mmHg | 2026-07-13 | completed | Blood pressure 116 to 120 over 72 to 74 at every visit |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Antiretroviral therapy with bictegravir, emtricitabine, and tenofovir alafenamide once daily, chosen for its high barrier to resistance and few interactions with his cardiac medicines; viral load and CD4 count every three months | completed | GL-DHHS-ART, GL-IAS-ART-2024, GL-HIVMA-PC-2020 |
| Infectious diseases consultation to co-manage HIV: the regimen and its interactions, opportunistic-infection prophylaxis, the monitoring schedule, and vaccines | completed | GL-DHHS-ART, GL-DHHS-OI |
| Toxoplasma maintenance therapy with trimethoprim-sulfamethoxazole double strength twice daily, which also prevents Pneumocystis pneumonia, until the CD4 count is above 200 for more than six months on suppressive therapy; blood count, potassium, and creatinine every three months while on it | completed | GL-DHHS-OI |
| Secondary prevention of coronary disease after two bypass operations: aspirin, high-intensity atorvastatin with ezetimibe added for an LDL goal below 55 mg/dL, blood pressure below 130/80, a heart-healthy diet, regular exercise, and a written chest-pain plan with sublingual nitroglycerin | completed | GL-CCD-2023, GL-CMID-2026 |
| Vaccines for adults with HIV: pneumococcal, hepatitis B with an antibody check afterwards, the two-dose meningococcal ACWY series, recombinant zoster, and seasonal influenza and COVID-19, with no live vaccines while the CD4 count is below 200 | completed | GL-CDC-IMZ-HIV, GL-HIVMA-PC-2020 |
| Person-first, confidential care: he decides who learns of his diagnosis; support with disclosure if and when he chooses, peer support, and depression screening with the PHQ-9 at intake and six months and the PHQ-2 at the preventive visit | completed | GL-HIVMA-PC-2020, GL-USPSTF-DEP-2023, GL-CMID-2026 |
Planned encounters
- 2026-01-12 — Establishing primary care for HIV after a recent diagnosis with cerebral toxoplasmosis, and for coronary artery disease after two bypass operations (ENC-001)
- 2026-02-09 — Four-week check of potassium and creatinine, second hepatitis B vaccine, and infectious diseases consultation (ENC-002)
- 2026-04-13 — Three-month HIV and lipid review (ENC-003)
- 2026-07-13 — Six-month HIV and coronary disease review with depression screening (ENC-004)
- 2026-08-17 — Periodic adult preventive visit (ENC-006)
- 2026-10-19 — Nine-month HIV review: decision to stop toxoplasmosis maintenance therapy (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Preventive Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Infectious Diseases referral
- Infectious Diseases consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Infectious Diseases referral (XML)
- Infectious Diseases consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Arthur Ashe (1943-1993) | Encyclopedia Virginia (Virginia Humanities) | scholarly |
| SRC-0002 | Lerner BH. Arthur Ashe and AIDS: Did the public have the right to know his diagnosis? | STAT | scholarly |
| SRC-0003 | Markel H. Arthur Ashe's other great serve: as activist for health | PBS NewsHour | scholarly |
| SRC-0004 | Arthur Ashe | Biography.com (A&E Television Networks) | other |
| SRC-0005 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the choice of TMP-SMX as toxoplasmosis maintenance, the timing of its discontinuation, and the LDL goal. |
| provenance review | not_started | Recent-death rule: only what Ashe made public himself and what was reported publicly, from Encyclopedia Virginia, STAT, PBS NewsHour, and Biography.com. The 1976 heart-attack date in one source is recorded as a dispute. |
| safe messaging review | not_started | HIV claims are marked sensitive; the language is person-first; disclosure is his own decision throughout; death recorded without detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.